Micro Imaging Technology, Inc. (MIT) announced the acquisition of Cellmyx, a company known for its quality medical tools in cosmetic surgery and regenerative medicine. This acquisition complements MIT's recent purchase of SaltMed/SaltFacial, enhancing its product portfolio and global manufacturing capabilities. Cellmyx specializes in autologous adipose grafting and has FDA clearance for its IntelliFat® BOD™ technology, which uses a patient's own fat for healing in orthopedic and cosmetic procedures. MIT aims to continue expanding in the aesthetics and regenerative medicine sectors, offering advanced medical solutions worldwide.
BlackRock reported a strong third quarter with adjusted earnings of $15.93 per share, beating estimates by a wide margin and marking a 38% increase year-over-year. Revenue grew 19% to $7.75 billion, driven by $205 billion in net client inflows, inclu...
Home BancShares will release its Q3 2026 earnings report on October 14, with analysts expecting earnings per share of $0.64 and revenue around $293-$294 million, marking a 5.5% revenue increase and 4.9% EPS growth from last year. The bank's P/E ratio...
Hyperion Materials & Technologies has acquired The Ultra-Met Company, a tungsten carbide manufacturer based in Urbana, Ohio, to expand its capabilities in serving the US aerospace and defense sectors. Ultra-Met works closely with the US Department of...
Morgan Stanley reported Q3 earnings per share of $3.03, surpassing analyst estimates of $2.93 and $2.83 consensus. Revenue reached $20.34 billion, a 12% increase year-over-year and above the $19.93 billion estimate. Strong equity trading and record w...
Bank of New York Mellon is set to report its Q3 2026 earnings, with analysts expecting earnings per share of $2.27 and revenue of $5.55 billion. This represents an 18.3% increase in earnings and a 9.5% rise in revenue compared to the previous year, d...
